CML patients treated with 2nd generation TKIs, revealed a significant increase of CD69+ NKT-like cells (Percentage: 16.2 ± 12.2 vs. 4.4 ± 5.3; p = 0.0022] (Figure 4D). This evidence concerns the gene CD69 and chronic myelogenous leukemia, BCR-ABL1 positive.